Abstract
The use of Botulinum Toxin Type A (BoNT-A) has become prevalent not only for therapeutic purposes but also for cosmetic applications. Among healthcare professionals, there has been an increase in BoNT-A administration within familial or friend circles. This rise has corresponded with a notable increase in cases of unilateral blepharoptosis presenting in emergency department admissions. This trend may be attributed to insufficient knowledge and experience regarding the proper dosing of BoNT-A, inadequate understanding of facial anatomy, or anatomical variations of the supraorbital foramen or neurovascular pedicle. While BoNT-A administration for reducing facial wrinkles may appear straightforward for a healthcare professional, a thorough understanding of anatomy and the causes and treatment of blepharoptosis is essential.
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a callDisclaimer: All third-party content on this website/platform is and will remain the property of their respective owners and is provided on "as is" basis without any warranties, express or implied. Use of third-party content does not indicate any affiliation, sponsorship with or endorsement by them. Any references to third-party content is to identify the corresponding services and shall be considered fair use under The CopyrightLaw.
